Why the study?
Does immunoadsorption improve cardiac function in patients with dilated cardiomyopathy?
Does immunoadsorption improve cardiac function in patients with dilated cardiomyopathy?
Immunoadsorption represents a potential therapeutic option for dilated cardiomyopathy by removing cardiodepressive autoantibodies and improving cardiac function.
Answers are grounded in this paper and cite their sources.
May support immunoadsorption in DCM; leaves open confirmation by randomized trials.
Abnormalities of the cellular and humoral immune system have been described in patients with dilated cardiomyopathy (DCM). Various circulating cardiac autoantibodies have been detected among DCM patients. Circulating antibodies are extractable by immunoadsorption (IA). Recent open controlled pilot studies have consequently shown that removal of circulating antibodies by IA induces improvement of cardiac function in DCM. IA, furthermore, decreases myocardial inflammation. In vitro data indicate that cardiodepressive antibodies play an important role in cardiac dysfunction of DCM patients; removal of these antibodies may accordingly represent the essential mechanism of IA in DCM. Furthermore, detection of cardiodepressive antibodies predicts hemodynamic benefits during IA. These antibodies belong to immunoglobulin G subclass 3. Recent data indicate that newly detected sarcolemmal Fc(gamma) receptors IIa are involved in the functional effects of cardiac autoantibodies.
No takes yet. Share an insight, caveat, or question.
Felix et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: